LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: LBH589|DRUG: Capecitabine|DRUG: Lapatinib
Sponsor: SCRI Development Innovations, LLC
Collaborators: Novartis